By educating consumers and health professionals about Champix, Pfizer New Zealand has helped thousands of Kiwis stop smoking—and once again caught the eye of head office.
Sometimes the best form of attack is defence. And that was certainly the case for Pfizer’s brave, innovative and hugely successful launch of Avigra into the local market to combat the effects of generic knock-offs.
2012 marks the 21st anniversary of the TVNZ-NZ Marketing Awards. And, in keeping with the traditions of the land, it emerged into adulthood this year with a new central theme of Everything Marketing and eight new categories, including financial, technology, automotive, utilities/communications, lifestyle/travel/leisure and sponsorship. And coming out at the head of the field with the supreme award was Volkswagen, with ex-Westpac and soon-to-be BNZ head of brand Ian Moody named as marketer of the year, Whittaker’s Jasmine Griffin named as rookie marketer of the year, Air New Zealand taking the marketing excellence award and Pfizer, Z Energy and Red Witch both picking up multiple awards.
The profitability of Big Pharma’s brands can collapse suddenly when patents expire and generic ‘knock offs’ flood the market. When this happens, the accepted norm is for up to 90 percent of an originator brand’s volume and share to be lost almost overnight and it’s an issue the industry hasn’t yet been able to resolve, so, typically, blockbuster compounds and their brands are simply written off or retired. But the local Pfizer branch wasn’t going to take the early patent expiry of Viagra in New Zealand lying down, so to speak, so it took the very unusual step of launching its own generic brand called Avigra and trying to migrate consumers to the cheaper, Pfizer-made alternative. And now, after a pun-laden press campaign and a bit of TV masthead activity, it’s stiffened its resolve by creating a new TVC.
Coinciding with a few new business wins, recent recognition at the Pharmacy Awards and the promotion of Robin Powell to creative director, BCG2 has expanded its creative department with four new arrivals: Alex Dyer, Anita Young, Matthias May and Matt Watts.
BCG2 Health’s Pfizer ‘FACTORy’ programme, originally developed in New Zealand in collaboration with Spitfire, and then launched into Australia, has won a Pfizer Human Health global award for commercial excellence and innovation.
bcg2 Health and Spitfire have snaffled a couple more Pfizer brands, after the two combined forces to win the haemophilia treatments pitch for the Xyntha and BeneFIX products in the Australian market against two Aussie agencies. This win adds to the New Zealand haemophilia business that was won in November last year.
‘International indie’ bcg2 has picked up an account double, and they’re at opposite ends of the ad spectrum: the Tongan tourism business and Pfizer’s Avigra from Viagra incumbents M&C Saatchi.